key: cord-0699204-552v9k67
authors: Racine-Brzostek, Sabrina E; Karbaschi, Mohsen; Gaebler, Christian; Klasse, P J; Yee, Jim; Caskey, Marina; Yang, He S; Hao, Ying; Sukhu, Ashley; Rand, Sophie; Chadburn, Amy; Shi, Yuanyuan; Zuk, Robert; Nussenzweig, Michel C; Cushing, Melissa M; Zhao, Zhen
title: TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability
date: 2021-04-29
journal: Clin Chem
DOI: 10.1093/clinchem/hvab069
sha: 11222afd8396c403b8346129d5afc69de0e911c9
doc_id: 699204
cord_uid: 552v9k67

BACKGROUND: Low initial SARS-CoV-2 antibody titers dropping to undetectable levels within months after infection have raised concerns over long term immunity. Both the antibody levels and avidity of the antibody-antigen interaction should be examined to understand the quality of the antibody response. METHODS: A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay built into the previously described SARS-CoV-2 TOP assays that measured total antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a versatile biosensor platform. TAb and SNAb levels were compared with avidity in previously infected individuals at 1.3 and 6.2 months post-infection in paired samples from 80 COVID-19 patients. Sera from SARS-CoV-2 vaccinated individuals were also evaluated for antibody avidity. RESULTS: The newly designed avidity assay in this TOP panel correlated well with a reference Bio-Layer Interferometry avidity assay (r=0.88). The imprecision of the TOP avidity assay was less than 10%. Although TAb and neutralization activity (by SNAb) decreased between 1.3 and 6.2 months post-infection, the antibody avidity increased significantly (P < 0.0001). Antibody avidity in 10 SARS-CoV-2 vaccinated individuals (median 28 days post-vaccination) was comparable to the measured antibody avidity in infected individuals (median 26 days post-infection). CONCLUSION: This highly precise and versatile TOP-Plus panel with the ability to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody levels and avidity of individual sera on one sensor can become a valuable asset in monitoring not only SARS-CoV-2-infected patients, but also the status of individuals’ COVID-19 vaccination response.

Coronavirus disease 2019 , caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to crippling levels of morbidity and mortality around the world.

(1) Seroprevalence studies have begun to show a larger extent of SARS-CoV-2 infections than initially reported because of the high prevalence of infected individuals with mild or no symptoms. (2, 3) However, lower SARS-CoV-2 IgG antibody levels have been reported in those with mild or no symptoms when compared to those with severe COVID-19.(4-7) Furthermore, emerging evidence suggests that SARS-CoV-2 antibodies in some asymptomatic carriers may diminish over time to levels below detection. (8) (9) (10) This decrease in antibody levels over time may include neutralizing SARS-CoV-2 antibodies, which play a vital role in viral clearance. (11) These observations raise the question of whether acquired immunity may be short lived and herd immunity protection may be less durable than anticipated. (12) While many studies focus on overall antibody titers, other factors are likely equally important in evaluating the humoral antibody response. Binding titers are determined by the antibody concentration and average affinity. Avidity can be defined as the strengthening of antibody binding through bi-or multivalency or as the functional affinity of the entire IgG, IgA, or IgM molecule, a net product of the intrinsic paratope-epitope affinity and the valency. (13) In the following we use the term avidity in the latter sense. Low avidity antibodies are typically produced early in the humoral immune response. (14, 15 ) Over time, with affinity maturation, the intrinsic affinity of the antibody-antigen interaction strengthens, and so does the functional affinity or avidity of bivalent IgG or classes of higher valency.

To evaluate whether these reported weak early antibody responses should be of clinical concern, various assays have emerged to help assess antibody avidity in the evaluation of the SARS-CoV-2 immune response. (16) (17) (18) (19) Antibody avidity may be measured in a variety of ways, including enzyme-linked immunosorbent assays, high performance liquid chromatography, capillary electrophoresis or single radial immunodiffusion. Although providing some insight into the functional affinity, these assays are often qualitative, labor intensive, low-throughput and display low accuracy and precision. Therefore, biosensor technologies such as Surface Plasmon

Resonance and Bio-Layer Interferometry (BLI) have become popular in monitoring the molecular binding between antigen and antibody in a real-time and cost effective manner. (20) This study describes a similar, yet novel, approach to evaluating the level and avidity of SARS-CoV-2 receptor-binding domain (RBD) antibodies using a testing-on-a-probe (TOP)-Plus panel (TOP-Plus) which includes a newly developed avidity assay and the previously described SARS-CoV-2 TOP assays (total antibody [TAb], surrogated neutralizing antibody [SNAb]) on a single versatile biosensor platform. This fully automated assay panel was used in the current study to evaluate and describe the antibody response and antibody avidity approximately 1 month and 6 months post symptom onset in 80 individuals previously diagnosed with COVID-

The antibody avidity in 10 vaccinated individuals approximately 1 month post SARS-CoV-2 vaccination (1 st dose) was also evaluated as an early demonstration of its use for monitoring the response to vaccination.

The details of participant characteristics and associated COVID-19 symptoms have been described previously. (21, 22) In summary, 80 adults aged 18-76 years who had been diagnosed with SARS-CoV-2 infection or had a confirmed SARS-CoV-2 exposure had blood specimen collected circa1.3 and circa 6.2 months post infection at the Rockefeller University Hospital.

Weill Cornell Medicine performed the antibody analyses as described below (Also see the online Supplemental Material).

Additional blood specimens were collected 1/2/2021-1/28/2021 from a separate cohort of 10 SARS-CoV-2 vaccinated (Moderna, mRNA-1273 vaccine) individuals. Specimens were collected 25-28 days after administration of the 1st vaccine dose but before the 2 nd dose (median 28 days post-vaccination). Samples were analyzed on the TOP-Plus biosensor, as described below.

The principle of the SARS-CoV-2 antibody avidity assay is similar to a previously described technology (23) that measured SARS-COV-2 antibodies at the tip of an RBD-coated quartz probe and used a biotinylated RBD and a Cy5-Streptavidin conjugate as the signaling elements.

However, the calculated relative dissociation rate (dR) allows for avidity testing in this new assay. (Figure 1 ) In short, a RBD precoated probe is sequentially incubated in microwells containing the sample (to capture SARS-CoV-2 specific antibodies), biotinylated RBD and Streptavidin-Cy5 conjugate along with washes between the incubation steps. After the initial fluorescent signal is measured (Signal_0), the probe with the immobilized immunocomplex enters into repetitive dissociation cycles with multiple incubations in phosphate-buffered saline with Tween ® -20 detergent (PBST, pH 7.4) as a dissociation buffer. After each incubation, the fluorescent signal is measured (Signal_t). Ultimately, a dissociation curve is constructed by plotting the normalized fluorescent signal (Signal_0/Signal_t) over time. The dR (1/s) is calculated from a function derived by fitting the dissociation curve assuming first order reaction kinetics.

The dissociation profile represents the rate of antibody dissociation from the RBD-coated probe.

For an accurate measurement of relative antibody dissociation rate, a limited but adequate amount of antibody is loaded on the probe surface. Loading higher amounts of antibody, determined by getting a high initial fluorescent signal (Signal_0) over a certain threshold, causes the formation of a packed multi-layer antibody construct on the probe surface. This leads to an inaccurate measurement as antibodies in a packed adsorbed layer cannot freely dissociate. Therefore, antibody packing density affects the dissociation measurement. On the other hand, sensitive measurements require adequate antibody loading as determined by the initial fluorescent signal above a certain level. Therefore, proper antibody loading must be within the proper range for accurate measurement. Samples with high antibody concentrations must be diluted for measurement. The appropriate initial fluorescent signal (which verifies an optimal antibody loading) was practically determined via a titration study to be in the range of 20-615RFU, as discussed below under analytical validation. The dilution factor was determined by measuring the initial fluorescent signal to fall within this proper signal range.

Of note, a lower dR reflects both affinity maturation and multivalent binding development.

Either a higher intrinsic binding strength of a paratope to RBD or addition of paratopes to the antibody structure results in a higher binding strength and a lower dR of a COVID-19 antibody-RBD pair. were identified as unmeasurable.

The SARS-CoV-2 antibody avidity assay was evaluated with 12 different purified antibodies against SARS-CoV-2 that were purchased from various vendors. (online Supplemental Table 1) These are recombinant human, rabbit or chimeric monoclonal and polyclonal antibodies of varying avidity levels to the RBD. A dissociation curve was generated utilizing pooled human sera from SARS-CoV-2 negative patients that were spiked with one of five antibodies and measured for avidity. The range of antibody concentrations used in the spike-in experiments are listed in online Supplemental Table 2 . dRs were determined at varying levels of Signal_0 by spiking the negative pooled sera with one of seven antibodies and measured for avidity.

The imprecision of the avidity assay and interference studies, including cross-reactivity studies, are described in the online Supplemental Material.

BLI measurements by the Gator (Gator Bio) was used to compare the avidity of 12 different purified COVID-19 antibodies (online Supplemental Table 1 ) to the TOP-Plus avidity assay.

Gator koff (dissociation-rate constant) measurement was performed at a fixed 10 ug/ml concentration level in a buffer containing 0.2% BSA and 0.02% Tween®-20. The TOP-Plus avidity assay measurements were performed using COVID-19 negative pooled serum spiked with one of these antibodies at a concentration level between 1-30 ug/ml (dependent on the appropriate fluorescence signal, range of 20-615 RFU, as described previously).

The SARS-CoV-2 total antibody TAb and SNAb assays were used to measure plasma TAb and SNAb antibodies against SARS-CoV-2. Plasma samples were assayed on the fully automated Pylon 3D analyzer (ET HealthCare), as previously described. (23, 24) Additional information may be found in the online Supplemental Material.

Statistical analysis details are provided in the online Supplemental Material.

As described in the assay description, accurate antibody dR requires only sufficient amounts of antibody to be loaded onto the probe surface. To evaluate and minimize this potential source of artifact associated with these label-free methods, dilution studies were performed using four specimens with high TAb measurements (in the range 1171-10872 RFU) and plotted against the dR. (Figure 2A) . Based on these studies, it was determined that the concentration-independent range for this assay was between 20 and 615 TAb RFU. (Figure 2B ) Therefore, any specimen with a TAb greater than 615 RFU was first diluted into the 20-615 RFU range prior to determining the dR.

The dissociation profiles of five different antibodies over time are demonstrated in Figure 3A .

Antibodies of varying RBD binding strength (online Supplemental Table 2 displayed different dRs and therefore, different dissociation profiles. The dRs were measured at proper antibody loading concentrations (0.06-30ug/ml, varying for different antibody) and the avidity measurement was found to be concentration (and therefore fluorescent signal) independent, as long as the initial fluorescent signal (Signal_0) is in the proper range ( Figure 3B ).

The imprecision was determined by running the high and low level of pooled patient samples (n=5-10) five times per day on five different days. The imprecision of the TOP avidity assay was 7.5% and 9.8% at two dR levels of 7.23 E-04 1/s and 4.66 E-04 1/s, respectively. The stability of samples at 2-4℃ refrigerated conditions was at least 5 days (variation: < 8%).

The TOP-Plus avidity assay was tested with common endogenous immunoassay interferences.

Avidity of two SARS-CoV-2 model purified antibodies first was measured in pooled SARS-CoV-2 negative serum, followed with spiking either biotin, bilirubin, hemoglobin or triglyceride and measuring antibody avidity in presence of each potential interferents. The TOP-Plus avidity assay displayed no interference from the listed components up to the tested concentrations.

(online Supplemental Table 3 No cross-reactivity was displayed in sera from HIV, EBV and Rheumatoid factor positive patients. All six samples were negative (online Supplemental 

BLI is a well-established technique in avidity measurement (25, 26) . To further validate the performance of TOP-Plus' avidity assay, Gator was used as a BLI reference method to measure the avidity of 12 purified COVID-19 antibodies. These values were compared to the avidity measured by the TOP-Plus avidity assay. It was found that the TOP-Plus avidity assay measurements correlated well (r=0.88) with the Gator measurements. (Figure 3C) 

It had been previously shown that TAb levels were significantly lower in the outpatient TAb levels were elevated in individuals who displayed persistence of symptoms beyond 6 weeks of symptom onset, when compared to those with no persistence of symptoms. (Figure 4B) Unlike TAb, antibody avidity remained unchanged across all WHO Ordinal Scales or in those with persistence of COVID-19 symptoms. (Figure 4C and 4D) .

TAb was evaluated in 80 individuals with confirmed or suspected COVID-19 (21, 22) (Figure 5A and 5C) . The decrease in TAb in this cohort mirrored the decrease in IgG and IgM levels that were measured using the same TOP biosensor (previously described in prior publications). (22, 24) SNAb had been previously shown (23) This reflected a median increase of 3.855x10 -4 /s or 39.8%. (Figure 5H) .

To demonstrate the avidity assay's potential clinical utility in evaluating the antibody response to The TOP-Plus avidity assay presented here measures the relative rate of dissociation of SARS-CoV-2 antibodies from the RBD antigen in plasma. However, this assay distinguishes itself from others in that it does not apply a chaotropic reagent. Therefore, the measured dR values better reflect the natural relative dissociation rate of antibodies from their target antigen than the conventional approaches where chaotropes may alter the native structure of the antigen or antibody. (13) Previously no one assay could evaluate total antibody levels, individual IgM and individual IgG levels as well as avidity. The new TOP-Plus biosensor panel comprises five assays, allowing for TAb, SNAb, IgG and IgM levels as well as avidity testing on the same platform using the same biosensor principles with specific application applied for each assay. This probe was able to assess the overall decreasing trend in TAb and SNAb (Figure 5) , in addition to the previously reported decreases in IgG and IgM. (22) Our findings of the decay in total SARS-CoV-2 antibodies and neutralization antibody activities are consistent with the previous studies. (10, 16, 21, (33) (34) (35) (36) (37) However, SARS-CoV-2 antibody avidity did not show the same pattern of diminishment during the first six months of infection The fact that only convalescent serum specimens were evaluated in this study is a limitation. The presented data cannot speak to the avidity maturation during the acute phase of infection and will require further studies to determine the full utility of TOP-Plus' avidity assay in acutely ill patients. As it is a newly evolved virus, it would be expected that the antibody avidity for SARS-CoV-2 antigens during primary infection would be weak and this avidity would increase over time. However, during the acute stages of infection, IgM could precede the IgG response and it could be postulated that the overall avidity may display an initial spike during the acute stage of infection due to the multimeric structure of the IgM antibody, masking the primary infection's expected weaker avidity.

In conclusion, this TOP-Plus biosensor panel is a versatile sensing platform with high precision and an ability to measure SARS-CoV-2 TAb, SNAb, individual IgG and IgM antibody levels along with the antibody's long-term avidity. This combination of all-in-one testing will be a valuable asset in monitoring not only convalescent COVID-19 patients, but also the status of individuals' COVID-19 vaccination response. 

The funding organizations played a direct role in the design of study, review and interpretation of data, preparation of manuscript, and final approval of manuscript. The funding organizations played no role in the choice of enrolled patients. 

WHO. Coronavirus Disease Dashboard

Seroprevalence of SARS-CoV-2-specific antibodies among adults in

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States

Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test

Healers Sustain Anti-SARS-CoV-2 Antibody Production

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Analysis of the application value of serum antibody detection for staging of COVID-19 infection

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection

Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control

How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses

Antibody avidity maturation during severe acute respiratory syndrome-associated coronavirus infection

Kinetics of SARS-CoV-2 Antibody

Avidity Maturation and Association with Disease Severity

Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors

Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay

Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates

Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Evolution of antibody immunity to SARS-CoV-2

Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients

SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semiquantitative immunoassays

Measuring protein-protein and protein-nucleic Acid interactions by biolayer interferometry

Label-free kinetic analysis of an antibody-antigen interaction using biolayer interferometry

COVID-19 Therapeutic Trial Synopsis

Are IgG antibody avidity assays useful in the diagnosis of infectious diseases? A review

Selection During Antigen-Driven B Cell Immune Responses: The Basis for High Affinity Antibody

Cancer Immunotherapy

The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity)

Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients